What is Chardan Capital’s Forecast for MNMD FY2025 Earnings?

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) – Research analysts at Chardan Capital issued their FY2025 earnings per share estimates for Mind Medicine (MindMed) in a report released on Monday, March 24th. Chardan Capital analyst R. Li anticipates that the company will earn ($1.70) per share for the year. Chardan Capital has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Mind Medicine (MindMed)’s current full-year earnings is ($1.35) per share.

Mind Medicine (MindMed) (NASDAQ:MNMD) last posted its quarterly earnings results on Thursday, March 6th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.08). During the same quarter last year, the business earned ($0.59) earnings per share.

A number of other equities research analysts also recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $55.00 price objective on shares of Mind Medicine (MindMed) in a research report on Friday, March 7th. Robert W. Baird lowered their target price on Mind Medicine (MindMed) from $27.00 to $16.00 and set an “outperform” rating for the company in a report on Friday, March 7th. Oppenheimer reissued an “outperform” rating and issued a $20.00 price target on shares of Mind Medicine (MindMed) in a report on Tuesday, December 17th. Finally, Evercore ISI began coverage on Mind Medicine (MindMed) in a research note on Tuesday, January 28th. They set an “outperform” rating and a $23.00 price objective for the company. Ten analysts have rated the stock with a buy rating and three have given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $25.11.

Mind Medicine (MindMed) Stock Down 2.9 %

MNMD stock opened at $6.58 on Thursday. The firm has a market cap of $495.92 million, a price-to-earnings ratio of -2.91 and a beta of 2.57. Mind Medicine has a 1-year low of $5.03 and a 1-year high of $12.22. The firm has a fifty day moving average price of $7.28 and a two-hundred day moving average price of $6.96. The company has a debt-to-equity ratio of 0.09, a current ratio of 9.00 and a quick ratio of 9.00.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Diadema Partners LP bought a new position in Mind Medicine (MindMed) during the 4th quarter valued at $33,000. Hollencrest Capital Management boosted its stake in Mind Medicine (MindMed) by 10,833.3% during the fourth quarter. Hollencrest Capital Management now owns 7,216 shares of the company’s stock valued at $50,000 after buying an additional 7,150 shares in the last quarter. King Wealth Management Group acquired a new position in Mind Medicine (MindMed) during the fourth quarter worth about $70,000. Virtus ETF Advisers LLC bought a new stake in Mind Medicine (MindMed) in the fourth quarter worth about $70,000. Finally, Sharpepoint LLC acquired a new stake in Mind Medicine (MindMed) in the 4th quarter valued at about $71,000. Institutional investors and hedge funds own 27.91% of the company’s stock.

Insiders Place Their Bets

In other Mind Medicine (MindMed) news, CEO Robert Barrow sold 21,208 shares of the firm’s stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $6.74, for a total transaction of $142,941.92. Following the transaction, the chief executive officer now owns 856,556 shares of the company’s stock, valued at approximately $5,773,187.44. This trade represents a 2.42 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Daniel Karlin sold 6,836 shares of the company’s stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $6.74, for a total transaction of $46,074.64. Following the completion of the sale, the insider now directly owns 446,177 shares of the company’s stock, valued at approximately $3,007,232.98. This represents a 1.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 30,391 shares of company stock worth $204,835. 2.26% of the stock is owned by company insiders.

About Mind Medicine (MindMed)

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.